DCTH DELCATH SYSTEMS, INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 872912 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY38.1%
TTM net income YoY455.4%
TTM EPS YoY433.3%
Revenue 3-yr CAGR270.3%
Net income 3-yr CAGR—
Margins
Gross margin87.6%
Operating margin5.2%
Net margin6.1%
FCF margin18.3%
EBITDA margin5.6%
Returns
ROE5.4%
ROA4.9%
ROIC (approx.)5.6%
Asset turnover0.80x
Leverage & solvency
Liabilities / assets10.4%
Debt / equity0.00x
Current ratio10.87x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.46x
Accruals ratio-12.0%
Payout ratio—
Capex / revenue2.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $85.23M | $37.20M |
| Cost of revenue | $11.80M | $6.19M |
| Gross profit | $73.43M | $31.02M |
| R&D expense | $29.25M | $13.87M |
| SG&A expense | $43.53M | $29.55M |
| Operating income | $660,000 | -$12.41M |
| Pretax income | $3.51M | -$26.39M |
| Income tax | $810,000 | $0 |
| Net income | $2.70M | -$26.39M |
| EBITDA | $898,000 | -$12.28M |
| EPS (basic) | 0.08 | -0.93 |
| EPS (diluted) | 0.07 | -0.93 |
| Weighted avg. shares (diluted) | 39.92M | 28.51M |
| Balance sheet | ||
| Cash & equivalents | $43.45M | $32.41M |
| Short-term investments | $47.58M | $20.82M |
| Receivables | $11.74M | $10.89M |
| Inventory | $10.25M | $6.93M |
| Current assets | $119.53M | $73.76M |
| PP&E, net | $3.17M | $1.79M |
| Total assets | $123.63M | $76.59M |
| Current liabilities | $10.95M | $6.14M |
| Long-term debt | — | $0 |
| Total debt | — | $0 |
| Total liabilities | $12.41M | $7.84M |
| Shareholders' equity | $111.22M | $68.75M |
| Net debt | — | -$32.41M |
| Shares outstanding | 34.69M | 33.06M |
| Cash flow statement | ||
| Operating cash flow | $22.52M | -$18.68M |
| Capital expenditure | $1.55M | $559,000 |
| Free cash flow | $20.97M | -$19.24M |
| Investing cash flow | -$26.59M | -$981,000 |
| Financing cash flow | $15.05M | $39.41M |
| Depreciation & amortization | $238,000 | $134,000 |
| Stock-based compensation | $24.23M | $9.77M |
| Share buybacks | $6.00M | $0 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.